News of Note—Gardasil-Cervarix divide, flu vaccines and more

newspapers
(Pixabay)

Here is some other vaccine news of note for the week:

> Starting from this fall, students in Quebec are receiving one shot of Merck & Co.’s Gardasil 9 and then later a shot of GlaxoSmithKline’s Cervarix to protect against HPV. Experts worry the new program will not build sufficient immunity to seven of the nine strains not covered in Cervarix. The Globe and Mail article

> Italy’s health minister, Giulia Grillo, from the vaccine-skeptic party Five Star Movement, has sacked the entire board of the country’s health advisory committee. The Guardian article

Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

> An ongoing shortage of GlaxoSmithKline’s popular shingles vaccine, Shingrix, has caused frustration among people waiting to get it. The Boston Globe article

> About 60% of people 60 and older in the U.S. have gotten a flu shot this season, according to new data from Clover Health. UPI article

> The global vaccines market is expected to reach $57.5 billion by 2025, up from from $33.7 billion in 2018, according to a report from Meticulous Research. Release

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.